Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Glofitamab, Polatuzumab Vedotin and Zanubrutinib in the First-line Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (DLBCL): A Single-center, Single-arm, Prospective, Phase II Trial

NCT07012980 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07012980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07012980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Glofitamab, Polatuzumab Vedotin and Zanubrutinib in the First-line Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (DLBCL): A Single-center, Single-arm, Prospective, Phase II Trial
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
July 31, 2026
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma